Optimizerx CORP 8-K filings

OptimizeRx reported a 30% year-over-year revenue decrease for Q2 2026, alongside a net loss, while reaffirming full-year guidance and announcing key finance leadership appointments.

OptimizeRx shareholders approved an increase of 1,000,000 shares to the 2021 Equity Incentive Plan at the 2026 Annual Meeting.

OptimizeRx Corporation announced the departure of Chief Commercial Officer Theresa Greco, effective June 15, 2026, under a separation and advisory agreement.

OptimizeRx Corporation announced a new $35 million senior secured credit facility and updated its fiscal year 2026 financial outlook, projecting revenues between $95-$100 million and maintaining adjusted EBITDA guidance.

OptimizeRx dismissed UHY and appointed Grant Thornton as its independent auditor, reporting no disagreements and reiterating a previously disclosed internal control material weakness.

OptimizeRx announced strong fourth quarter and full year 2025 financial results, including record net income and adjusted EBITDA, alongside updated 2026 guidance and a new $10 million share repurchase program.

OptimizeRx Corporation announced robust third-quarter 2025 financial results, including a 22% revenue increase and a significant jump in net income, leading to an upward revision of its full-year 2025 guidance and introduction of 2026 projections.

OptimizeRx Corporation announced significant leadership advancements, including a new Chief Operating Officer and expanded roles for key executives, to accelerate its strategic growth and profitability initiatives.

OptimizeRx Corporation reported robust second quarter 2025 financial results, with revenue increasing 55% year-over-year and significantly raising its full-year 2025 guidance.

OptimizeRx Corporation announced the appointment of its Chief Executive Officer, Stephen Silvestro, to its Board of Directors, effective June 20, 2025, following an increase in the board's size to six members.

OptimizeRx Corporation announced the results of its 2025 Annual Meeting of Stockholders, where all five director nominees were elected, executive compensation was approved on an advisory basis, and UHY LLP was ratified as the independent auditor.

OptimizeRx announced positive Q1 2025 results, including an 11% increase in revenue and raised its full-year 2025 revenue and adjusted EBITDA guidance.

OptimizeRx Corporation announces plans to appoint a new independent director in the second half of 2025 and resolves concerns with Whetstone Capital Advisors.

OptimizeRx announced strong financial results for Q4 and full year 2024, with revenue increases and positive momentum heading into 2025.

OptimizeRx Corporation announced the appointment of Stephen Silvestro as Chief Executive Officer, effective March 10, 2025, as the company focuses on future growth and shareholder value creation.

William Febbo has stepped down as CEO of OptimizeRx, entering into a separation agreement that includes severance benefits and a short-term advisory role.

OptimizeRx announced the departure of CEO William Febbo, effective December 31, 2024, and the appointment of Stephen Silvestro as interim CEO while a search for a permanent replacement is conducted.

OptimizeRx reported a 30% year-over-year increase in revenue for the third quarter of 2024, reaching $21.3 million, alongside a net loss of $9.1 million.

OptimizeRx reported a 36% year-over-year increase in Q2 revenue, reaching $18.8 million, alongside a 50% increase in gross profit, although a timing issue with a major deal impacted overall results.

OptimizeRx Corporation's stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the available shares by 1.95 million to a total of 4.45 million, at their 2024 Annual Meeting.

OptimizeRx announced a 51% year-over-year increase in revenue for the first quarter of 2024, driven by strong performance of its AI-enabled platform.

OptimizeRx reports preliminary first quarter revenue growth exceeding 40% year-over-year, driven by strong organic growth and the acquisition of Medicx Health.

OptimizeRx announced a 44% year-over-year increase in Q4 revenue to $28.4 million, driven by organic growth and the acquisition of Medicx Health.

OptimizeRx has extended its financial reporting deadline to April 15th and reported a 44% year-over-year revenue increase for the fourth quarter of 2023, driven by strong organic growth and the acquisition of Medicx Health.

OptimizeRx reaffirms its prior FY2023 revenue and adjusted EBITDA estimates while updating its 2024 revenue guidance due to a change in accounting treatment.

OptimizeRx has announced changes to its Board of Directors, including a new Chairperson and the appointment of a new member, to align with the company's growth plans.